IMAB

I-Mab

2.62

0.61+30.35%

After Hours: 2.532 -0.09 -3.37%19:58 08/01 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.260/2.010

TODAY RANGE2.250-3.440

VOL44.55M

MARKET CAP213.95M

52 WEEK RANGE0.5950-3.440

AVG VOL (3M)1.30M

% TURNOVER54.56%

TURNOVER--

P/E (TTM)-28.8864

% RANGE59.20%

EPS(TTM)-0.0907

P/E(FORWARD)-14.5556

P/B1.079

BVPS2.429

DIVIDEND--

P/S903.45

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP152.60M

SHARES OUTSTANDING81.66M

NEXT EARNINGS08/26-09/01

FREE FLOAT58.25M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

Benzinga·13h ago
12 Health Care Stocks Moving In Friday's Intraday Session
TipRanks·17h ago
Everest Medicines announces strategic equity investment in I-Mab
Benzinga·17h ago
Everest To Invest $30.9M In Cash In I-Mab; Inclusive Of I-MAB Shares Already Held By Everest, Pro Forma Ownership Will Be 16.1%
Reuters·17h ago
Everest Medicines Ltd. Expands Stake with $30.9 Million Investment in U.S.-Based Biotech Firm I-Mab
Seeking Alpha·17h ago
I-Mab prices $65M ADS offering
TipRanks·18h ago
I-Mab prices 33.3M ADSs at $1.95 in underwritten offering
Reuters·18h ago
I-MAB ANNOUNCES PRICING OF $65 MILLION UNDERWRITTEN OFFERING OF AMERICAN DEPOSITARY SHARES
TipRanks·19h ago
I-MAB Announces Preliminary Financial Results for Mid-2025
Barchart·23h ago
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
Benzinga·2d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Seeking Alpha·07/17 13:38
I-Mab to buy Bridge Health Biotech
TipRanks·07/17 11:28
I-Mab Acquires Bridge Health to Boost Givastomig Portfolio
TipRanks·07/17 11:11
I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech
Reuters·07/17 11:05
I-Mab Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026
Reuters·07/17 11:00
I-MAB - TO PAY $1.8 MLN UPFRONT AND $1.2 MLN THROUGH 2027

Same Industry

Name/Symbol

Change%

Price

I-Mab

IMAB

+30.35%

2.62

McKesson

MCK

+0.76%

698.80

Biogen Inc

BIIB

+3.09%

131.95

Amgen Inc

AMGN

+0.60%

296.88

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0301

Lilly Eli & Co

LLY

+3.01%

762.33

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-0.89%

1.11

Johnson & Johnson

JNJ

+1.57%

167.33

Abbvie Inc

ABBV

+3.28%

195.22

Zoetis Inc

ZTS

+1.09%

147.38

Gilead Sciences Inc

GILD

+0.79%

113.18

Novo-Nordisk A/S

NVO

+2.38%

48.19

Bristol-Myers Squibb Co

BMY

+2.12%

44.23

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.86%

23.49

Sanofi FR

SNY

+2.43%

46.75

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+1.37%

115.30

Dr Reddys Labs

RDY

-1.97%

13.94

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English